Back to results
US 10,894,823 B2Granted
Trispecific inhibitors for cancer treatment
AssigneeGensun Biopharma Inc.
InventorsJackie Sheng, Bo Liu, Haiqun Jia
Life of this patent
Estimating the term…
Abstract
A trispecific inhibitor for treating cancer includes a first targeting domain having a binding specificity conferred by a VEGF binding antagonist; a second targeting domain having a binding specificity conferred by an immune checkpoint regulator binding antagonist; and a third targeting domain having a binding specificity conferred by a Tie2 tyrosine kinase receptor binding antagonist. The targeting domains may contain one or more antibody variable regions, peptide inhibitors, dominant negative proteins, small molecule drugs or combinations thereof.
Claims7
A trispecific antibody, comprising:
- a first targeting domain that binds specifically to human PD 1;
- a second targeting domain that blocks binding of human VEGF-A to VEGFR-2;
- and
- a third targeting domain that binds specifically to human Tie2 tyrosine kinase receptor,
- wherein the trispecific antibody comprises a heavy chain/light chain combination selected from the group consisting of SEQ ID NOS:20 and 21, SEQ ID NOS:22 and 23, SEQ ID NOS:24 and 25, SEQ ID NOS:26 and 27, and SEQ ID NOS:38 and 39, and
- wherein the trispecific antibody exhibits a binding activity to human PD-1 within the same order of magnitude to that of nivolumab, a binding activity to VEGF within the same order of magnitude to that of bevacizumab and a binding activity to human Ang-2 within the same order of magnitude that of trebananib.
3 more elements
Dependencies are inferred from the claim text.